logo

BBIO

BridgeBio Pharma·NASDAQ
--
--(--)
--
--(--)
3.79 / 10
Netural

Fundamental breakdown reveals concerning profile (3.8/10). Supportive elements: Revenue-MV and Profit-MV, however risks emerge in Net profit / Total profit (%) and Asset-MV. This suggests prudent positioning.

Fundamental(3.79)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-2.11
Score2/3
Weight24.22%
1M Return11.69%
Inventory turnover ratio
Value0.52
Score2/3
Weight-4.03%
1M Return-2.63%
Gross profit margin (%)
Value96.31
Score3/3
Weight21.33%
1M Return10.80%
Profit-MV
Value0.46
Score2/3
Weight15.89%
1M Return7.79%
PB-ROE
Value8.85
Score2/3
Weight22.31%
1M Return10.68%
Current assets turnover ratio
Value0.45
Score1/3
Weight-0.80%
1M Return-0.48%
Fixed assets turnover ratio
Value54.19
Score2/3
Weight0.21%
1M Return0.12%
Asset-MV
Value-0.50
Score0/3
Weight5.43%
1M Return2.94%
Cash-MV
Value-0.07
Score2/3
Weight15.91%
1M Return7.73%
Net profit / Total profit (%)
Value100.10
Score0/3
Weight-0.47%
1M Return-0.30%
Is BBIO fundamentally strong?
  • BBIO scores 3.79/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, -227.74% net margin, -16.45 P/E ratio, -6.82 P/B ratio, and -73.97% earnings growth, these metrics solidify its Netural investment rating.